


<b>Form PTO-1449 Substitute</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b> <b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)	Application Number	10/037,341
	Filing Date	January 4, 2002
	First Named Inventor	David Baltimore
	Art Unit	1636
	Examiner Name	C. Hibbert
Attorney Docket No.		75723- ZA/JPW/GJG/CS



### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Advisory Action issued February 14, 2008 in Merged Reexamination Control Nos. 90/007,503 and 90/007,828;	
	2	Brief of Plaintiffs/Counterclaim Defendants-Appellees Amgen Inc., et al., filed January 28, 2009 in the concurrent litigation captioned <i>Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.</i> , U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023; and	
	3	Reply Brief for Appellants, ARIAD Pharmaceuticals, Inc., et al., filed February 17, 2009 in the concurrent litigation captioned <i>Amgen Inc., et al. v. ARIAD Pharmaceuticals, Inc., et al.</i> , U.S. Court of Appeals for the Federal Circuit, Docket No. 2009-1023;	

**EXAMINER  
SIGNATURE**
**DATE CONSIDERED**

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.  
 Serial No.: 10/037,341  
 Filed: January 4, 2002  
**Exhibit A**